BSBow Suprasert

Bow Suprasert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Bow Suprasert has a total of 58 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Photovoice as contributing to resiliency among trans women experiencing individual and intersecting HIV and anti-trans stigma in madhesh province, Nepal

    by Swagata Banik, Manisha Dhakal, Sanjay Sharma, Jose Francisco, Glenda N. Baguso, Dichen Moktan, Bow Suprasert, Erin C. Wilson

  • Community Insights on the Acceptability of Location-enabled Devices to Improve Retention in Care and Prevention Among People Who Inject Drugs, Oakland and San Francisco, California

    by Bow Suprasert, Raul Ruiz, Paavani Lella, Iris R. O’NEal, Gueslyn Velasquez, Glenda N. Baguso, Erin C. Wilson, Willi McFarland, Lila A. Sheira

  • Open Access

    A Decade of Improvement and Signs of Decline in PrEP Awareness and Use in Young Trans Women

    by Colbey Ricklefs, Bow Suprasert, Willi McFarland, Erin C. Wilson

    The risk of HIV is significantly higher in transgender women compared to the general population, with young trans women having higher incidence compared to older trans women. Effective efforts to ensure PrEP uptake and persistence among young trans women is key to addressing the HIV epidemic in the U.S. We analyzed serial cross-sectional data from the Trans women Empowered to Advance Community Health (TEACH) studies conducted in San Francisco in 2013, 2016–2017, 2019–2020, and 2023–2024. Our study included 83 young adult (18–26 years old) trans women living without HIV. We used the Cochran-Armitage test for trends to assess changes in PrEP awareness, use, and key HIV risk and preventive behaviors. PrEP awareness among young trans women significantly increased from 6% in 2013, 94% in 2016–2017, 100.0% in 2019–2020, and 86% in 2023–2024 (z = 7.96, p < 0.001). PrEP use also significantly increased from 0% in 2013, 19% in 2016–2017, 46% in 2019–2020, and 36% in 2023–2024 (z = 9.90, p < 0.001). Meanwhile, condomless sex in the last 12 months has risen from 33% in 2013 to 86% in 2023–2024 (z = 4.15, p < 0.001). PrEP awareness and use have significantly increased among young trans women in San Francisco since FDA approval in 2012. However, our study points to a potential leveling off or decrease in PrEP awareness and use in recent years. Furthermore, PrEP use still lags need. Young trans women must be prioritized in PrEP awareness and demand creation efforts in addition to efforts to support adherence and persistence.

  • Progress toward hepatitis C elimination among people who inject drugs in San Francisco, 2018 – 2024

    by Christopher J. Hernandez, Bow Suprasert, Glenda Baguso, Erin C. Wilson, Willi McFarland


  • Open Access

    Hooked before the first injection: The role of prescription opioids in early injection drug use initiation in San Francisco

    by Abubakar Ibrahim Elbur, Bow Suprasert, Ali Mirzazadeh, Erin C. Wilson, Willi McFarland


  • Shigellosis awareness and diagnosis in community surveys of men who have sex with men and trans women, San Francisco, California, United States

    by Xinru Tsai, Bow Suprasert, Erin C. Wilson, Willi McFarland

    Background: Shigellosis has increasingly and disproportionately affected sexual and gender minority populations. Although historically considered a food- and waterborne illness, Shigella can also be transmitted sexually. This study assessed awareness of shigellosis among men who have sex with men (MSM) and trans women, and examined the burden of infection and treatment among MSM in San Francisco. Methods: Data were drawn from the most recent National HIV Behavioral Surveillance (NHBS) cycles conducted among MSM (June–November 2023) and trans women (July 2023–May 2024) in San Francisco. The MSM cycle included three Shigella-related items (awareness, history of diagnosis, and treatment), while the trans women cycle included two items (past and recent history of diagnosis). Multivariable logistic regression was conducted to examine factors associated with shigellosis awareness among MSM. Results: Among 545 MSM, 35.4% were aware of shigellosis, 5.5% reported ever having the infection, and 5.1% sought treatment. Among 339 trans women, 1.2% reported ever having shigellosis, and 0.3% within the past 12 months. Among MSM, awareness was higher among White participants, those with postgraduate education, those who saw a healthcare provider, and those who tested positive for a bacterial STI in the past 12 months. Conclusions: Despite global outbreaks among MSM, awareness of shigellosis within sexual and gender minority communities remains low, and the burden of infection is likely underestimated. Tailored, stigma-sensitive sexual health promotion integrating shigellosis into broader STI prevention efforts, alongside improved provider training, is essential to ensure equitable care and reduce future outbreak risk.

  • Open Access

    Understanding the role of overdose witnesses: responses and characteristics of people who inject drugs in Oakland and San Francisco

    by Bow Suprasert, Raul Ruiz, Jose Francisco, Paavani Lella, Iris R. O’NEal, Gueslyn Velasquez, Glenda N. Baguso, Glenn-Milo Santos, Erin C. Wilson, Eileen F. Dunne, et al.

    Background: Overdose is a significant cause of mortality in the United States. People who inject drugs (PWID) are uniquely positioned to witness and reverse overdoses. This study assesses overdose responses and factors associated with witnessing overdose among PWID. Methods: Data originate from baseline surveys for a longitudinal study of PWID in Oakland and San Francisco, California, collected between April 2024 and March 2025. Multivariable logistic regression identified factors associated with witnessing overdoses. Results: Of 597 PWID, 464 (77.7%) witnessed at least one overdose in the past 3 months, with an average of 13.4 (SD = 28.2) and a median of 6 (IQR = 3–15) overdoses. Among those, 30 (6.5%) reported only calling 911, 50 (10.8%) reported taking no action, 172 (37.2%) reported only using naloxone to reverse overdoses, and 210 (45.5%) used naloxone in conjunction with calling 911. The adjusted odds of witnessing overdoses were 2.2 times higher among unsheltered PWID (vs. sheltered, p < 0.001), 3.1 times higher among those in San Francisco (vs. Oakland, p < 0.001), 4.6 times higher among those who experienced non-fatal overdose themselves (vs. not, p = 0.002), 2.8 times higher among those sharing needles (vs. not, p = 0.015), and 1.9 times higher among those injecting fentanyl (vs. did not, p = 0.006) in the past 3 months. Conclusions: Nearly four in five PWID in Oakland and San Francisco recently witnessed an overdose. Witnesses are at greater risk of non-fatal overdose and may be the first to respond when those they inject with overdose. Targeting naloxone distributions to PWID who are characteristically more likely to witness overdoses may prevent additional drug-related deaths.


  • Not Getting to Zero HIV Among Men Who Have Sex with Men in San Francisco Despite High Care Continuum and Prevention Targets

    by Bow Suprasert, Moranda Tate, Robert Williams, Danyion Reagan, Jose Francisco, Katherine McNaughton, Jaiden Anakwenze, Erin C. Wilson, Willi McFarland

    New HIV diagnoses among men who have sex with men (MSM) in San Francisco decreased by 77% from 2012 to 2021, presenting an encouraging trajectory toward zero infections by 2030. Unfortunately, the trajectory has slowed in recent years, with an uptick in new diagnoses from 2021 to 2022. We assessed the current HIV epidemic status and progress towards achieving the 95-95-95 HIV care continuum and prevention targets among MSM in San Francisco. Time-location sampling was used to sample MSM, recruiting at physical and online venues at randomly chosen venue-day-time periods from June to November 2023. HIV status was obtained by rapid testing; HIV care and prevention engagement were self-reported. Among 545 MSM, HIV prevalence was 24.4%. Prevalence was highest (48.8%) among Black/African American MSM. Of 132 living with HIV, 97.7% were aware of their status, of whom 97.7% were on antiretroviral therapy (ART), of whom 90.5% reported being virally suppressed. Among MSM not living with HIV, 80.0% had an HIV test, 56.5% used pre-exposure prophylaxis (PrEP), 27.9% consistently used condoms, and 9.2% used post-exposure prophylaxis (PEP) in the past 12 months. MSM in San Francisco in 2023 exceeded the first (status awareness) and second (ART use) pillars of the shared global 95-95-95 targets, and was greater than 90% for the third (viral suppression). Our current prevention tools are reaching diminishing returns. New medical interventions may also have a marginal impact unless we first address social and structural barriers that continue to result in HIV disparities and PrEP inequities.


  • Not Getting to Zero HIV Infections Among People Who Inject Drugs in San Francisco, California

    by Moranda Tate, Bow Suprasert, Danyion Reagan, Katherine McNaughton, Raul Ruiz, Alex Marr, Kelly D. Taylor, Glenda Baguso, Erin C. Wilson, Willi McFarland

    We analyzed data from San Francisco’s National HIV Behavioral Surveillance for 2018 and 2022 to assess progress towards getting to zero HIV infections among people who inject drugs (PWID). HIV prevalence showed little change from 2018 (10.9%) to 2022 (11.4%). UNAIDS 90-90-90 targets were not met during the four-year interval, accompanied by a drop in HIV testing in the last year (from 73.5 to 43.4%, X2(1) = 82.76, p < 0.001). We found no evidence that the HIV epidemic is heading towards zero among PWID. Our data are a wakeup call to revitalize our HIV epidemic response, especially for marginalized populations.


  • Sample composition and HIV prevention indicator differences using physical vs virtual venue recruitment of men who have sex with men in San Francisco

    by Izzy Chiu, Moranda Tate, Dillon Trujillo, Bow Suprasert, Alex Marr, Sean Arayasirikul, Erin C Wilson, Henry F Raymond, Willi McFarland

    During the COVID-19 pandemic, the sampling method for the National HIV Behavioral Surveillance (NHBS) in San Francisco changed from physical venue time-location sampling (TLS) to online or virtual venue TLS for men who have sex with men (MSM). We present differences in the samples of MSM recruited using physical venue TLS in 2017 and virtual venue TLS in 2021. We further assess changes in preventive and risk behaviors from 2017 to 2021 after controlling for differences in the sample compositions with multivariable Poisson models using generalized linear models with robust standard errors. Both sampling methods exceeded their targeted sample size of 500 (physical venue TLS n = 502, virtual venue TLS n = 505). Compared to physical venue TLS, the virtual venue TLS sample had fewer persons experiencing homelessness and incarceration, and more persons with health insurance and postgraduate degrees. After adjusting for these differences and age, race, and employment status, pre-exposure prophylaxis use increased from 2017 to 2021. The use of several noninjection drugs also increased, namely marijuana, poppers, ketamine, psilocybin, and LSD. We found virtual venue recruitment of MSM to be a viable approach for tracking trends in HIV-related behaviors, with notable appeal given possible future pandemic lockdowns of physical venues and changing socialization patterns.